GC Genome Corporation

GC Genome Corporation, a South Korean clinical genomics company founded in 2013 and headquartered in Yongin-si, specializes in a broad spectrum of genetic analysis services. The firm offers extensive cancer diagnostics, including hereditary cancer, blood cancer, homologous recombination deficiency tests (under the Green Plan brand), as well as advanced liquid biopsy options like Guardant360 for comprehensive blood genetic profiling and Guardant Reveal for detecting microscopic residual disease and monitoring recurrence. Their rare disease testing covers chromosomal microarray, targeted exome, whole exome, and diagnostic genome sequencing. Additionally, GC Genome provides innovative tools for early multi-cancer screening (ai-CANCERCH), personalized nutrition (Jins Sketch), identification of disease susceptibility genes (Genome Health and Risk Screen), symbiotic microorganism analysis (Green Biome), proactive health management (Genome Screen), biological age assessment (Telorisk), and drug compatibility DNA testing. The company further extends its offerings to prenatal and newborn care with non-invasive fetal chromosomal abnormality screening (G-NIPT), advanced fetal chromosomal diagnosis (Prenatal CMA), and newborn genetic screening (i-screen). Specialized services also include dd-cfDNA, a single nucleotide polymorphism test for cell-free nucleic acid from organ transplant donors.